NEWS FROM JANSSEN RHEUMATOLOGY

The news section in rheumatology, is intended for bringing the latest relevant updates in the field of rheumatology, more specifically for the
disease of Psoriatic Arthritis.

 

20 NOVEMBER 2020

European Commission has approved TREMFYA® (guselkumab) for the treatment of adult patients with
active psoriatic arthritis (PsA) who have had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy.


16 OCTOBER 2020

Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA® (guselkumab) in the Treatment
of Active Psoriatic Arthritis (PsA) in the European Union (EU).


14 JULY 2020

TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin
(IL)-23 Inhibitor for Active Psoriatic Arthritis.


20 OCTOBER 2019

Janssen Seeks to Expand Use of TREMFYA® (guselkumab) in the Treatment of Adults with Active Psoriatic
Arthritis.

 

 

 

CP-208851 - 03-Feb-2021